Shots:

• The companies will evaluate SpringWorks’ nirogacestat (GSI) + Seagen’s SEA-BCMA (Ab targeting BCMA) in patients with RRMM. The companies anticipate commencement of the study in H2’21
• Seagen to sponsor & conduct a P-I study to evaluate the safety- tolerability- and preliminary efficacy of the combination- and will assume all costs of study- other than the expenses related to the manufacturing of nirogacestat and IP rights
• The companies will form a joint development committee to manage the clinical study. Additionally- SpringWorks is conducting a global P-III DeFi Trial to evaluate nirogacestat as monothx. in adults with progressing desmoid tumors

  | Ref: Globe Newswire | Image: Neurofibromatosis Network